

Symatix[®]

An alternative to Amniotic Membrane



ELECTROSPINNING[®]
COMPANY

A global tissue shortage driven by different factors

Developing nations

Lack organised **tissue procurement** system

Tissue banking **infrastructure non-existent** or too small to cope with massive demand

Human tissue **regulation in infancy**



Developed nations

Donor tissue **demand outstretches supply** driven by aging population & unhealthy lifestyle

Quality variation due to **donor variability**

Relentless **cost-saving policies** on healthcare exert pressure on tissue availability

Changes in **regulatory** environment

Amniotic Membranes (AM): clinical use & shortfalls



AM successfully used in clinic yet remains subject to:

- Variation due to donor variability
- Costly serology and sub-zero storage facilities
- Fragmented human tissue regulation where the need is highest = developing countries
- Donor availability for supply

Symatix[®]: Addressing the AM shortcomings

USP

Synthetic

Mass Producible

Sustainable

Consistent

Advantages

No serology
No donor traceability
No tissue regulation

Unlimited production


No expensive facility needed
No high utilities bill

Minimal variation in batches

Product	Cost	Availability	Consistency
Amniotic membrane	↑↑	↓↓	↓↓
Symatix	↓↓	↑↑	↑↑

Symatix: Material and Intangible value

Symatix = Composite membrane comprising hyaluronic acid reinforced with synthetic degradable polymer fibres



Similar macroscopic and microscopic appearance to AM

	AM	Symatix
Tuneable?	no	Yes
Drug delivery?	no	Yes
Sterile?	no	Yes

Intangible value

Public IP

- Patent application (PCT stage)
- Registered trade mark

Trade secrets

- Production process

Know how

- Process validation and verification
- Scale up manufacturing

Relationships

- KOL advisors



Prof. Dua



Dr. Sangwan


Business Intelligence

- Market data
- IP landscape

Quality

- ISO13485 certified
- DHR available

Symatix: Development timeline



Fully supported by Electrospinning Company

Deliverables

- PoC data package
- Completed ISO10993 biocompatibility studies
- Scalable manufacturing + complete design history file
- KOL support in ophthalmology
- Patent & trade secret package

In partnership

Looking for partner to

- Conduct clinical trial stages in collaboration with Electrospinning Company
- Become legal manufacturer of Symatix
- Jointly develop and execute market launches in key markets
- expand use of Symatix in ophthalmology, wound care and beyond

Symatix: the company and team



Company

- Privately held SME
- Contract design, development, manufacturing services
- Electrospinning technology
- ISO 13485 certification since 2015
- Medical Devices and Regenerative Medicine
- Strategic relationship with Confluent Medical technologies
- Harwell Innovation Campus (near Oxford)

Team

Technical

- Mehri Behbehani, PhD
- Rob McKean, PhD

Commercial

- Gianpaolo Bruti, PhD
- Marco Thio, PhD

Advisory

- Prof. Harminder Dua
- Virender Sangwan, PhD

The Electrospinning Company Ltd

Unit 5 Zephyr Building, Eighth Street, Harwell Campus,
Didcot, Oxfordshire, OX11 0RL, United Kingdom

Call: +44 (0)845 388 8856 Email: info@electrospinning.co.uk
www.electrospinning.co.uk

Copyright 2020 Electrospinning Company



ELECTROSPINNING[®]
COMPANY